INFI:NAS (USA) Also trade in: Germany

Infinity Pharmaceuticals Inc

$ 1.51 -0.06 (-3.82%)
Volume: 95,680 Avg Vol (1m): 253,692
Market Cap $: 85.95 Mil Enterprise Value $: 27.36 Mil
P/E (TTM): 0.00 P/B: 1.64
Earnings Power Value -67.41
Net Current Asset Value 0.92
Tangible Book 0.92
Projected FCF -7.23
Median P/S Value 1.53
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt No Debt
Equity-to-Asset 0.87
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.07
DISTRESS
GREY
SAFE
Beneish M-Score -0.60
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -3808.43%
WACC 17.27%

Profitability & Growth : 4/10

Current vs industry vs history
Operating Margin % -53.86
Net Margin % -50.81
ROE % -22.42
ROA % -19.62
ROC (Joel Greenblatt) % -325.26
3-Year Total Revenue Growth Rate -41.20
N/A
3-Year Total EBITDA Growth Rate 55.50
3-Year EPS w/o NRI Growth Rate 57.60

» INFI's 30-Y Financials

Financials (Next Earnings Date: 2019-05-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:INFI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:OTIC XTAE:CBI NAS:BDSI OTCPK:HPPI NAS:PRQR ROCO:4130 NAS:TRVN OTCPK:CYDY NAS:AXON NAS:CKPT LSE:DDDD TPE:1786 NAS:CFRX TSE:2370 NAS:OMED NAS:CERC NAS:BTAI OTCPK:DGJI TSE:4572 WAR:BIO
Traded in other countries I3F.Germany
Address 784 Memorial Drive, Cambridge, MA, USA, 02139
Infinity is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products, and those under development, include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments.

Ratios

Current vs industry vs history
PB Ratio 1.64
PS Ratio 3.92
EV-to-EBIT -2.42
EV-to-EBITDA -2.45
EV-to-Revenue 1.23
Current Ratio 7.75
Quick Ratio 7.75
Days Sales Outstanding 362.59

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.00

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.64
Price-to-Median-PS-Value 0.99
Earnings Yield (Joel Greenblatt) % -41.35

More Statistics

Revenue (TTM) (Mil) $ 22.15
EPS (TTM) $ -0.21
Beta 2.53
Volatility % 70.36
52-Week Range $ 1 - 2.92
Shares Outstanding (Mil) 56.93

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y